Loxiglumide
Title: Loxiglumide
CAS Registry Number: 107097-80-3
CAS Name: 4-[(3,4-Dichlorobenzoyl)amino]-5-[(3-methoxypropyl)pentylamino]-5-oxopentanoic acid
Additional Names: (±)-4-(3,4-dichlorobenzamido)-N-(3-methoxypropyl)-N-pentylglutaramic acid
Manufacturers' Codes: CR-1505
Molecular Formula: C21H30Cl2N2O5
Molecular Weight: 461.38
Percent Composition: C 54.67%, H 6.55%, Cl 15.37%, N 6.07%, O 17.34%
Literature References: Cholecystokinin type-1 (CCK-1) antagonist. Prepn: F. Makovec et al., WO 8703869; eidem, US 4769389 (1987, 1988 both to Rotta). Pharmacology and receptor binding: I. Setnikar et al., Arzneim.-Forsch. 37, 703 (1987). Pharmacokinetics: idem et al., ibid. 38, 716 (1988). Effect on bilio-pancreatic secretion: W. E. Schmidt et al., Digestion 46, Suppl. 2, 232 (1990). Clinical evaluation in irritable bowel syndrome: P. A. Cann et al., Ann. N.Y. Acad. Sci. 713, 449 (1994); in nonulcer dyspepsia: A. S. B. Chua et al. ibid. 451; in pancreatitis: K. Shiratori et al., Pancreas 25, e1 (2002).
Properties: Crystals from acetone, mp 113-115°. pKa ~5. Soly in water: 0.01%.
Melting point: mp 113-115°
pKa: pKa ~5
 
Derivative Type: (R)-Form
CAS Registry Number: 119817-90-2
Additional Names: Dexloxiglumide
Manufacturers' Codes: CR-2017
Literature References: HPLC determn in plasma: R. Brodie et al., J. Chromatogr. B 784, 91 (2003). In vitro biopharmaceutical properties: S. Tolle-Sander et al., J. Pharm. Sci. 92, 1968 (2003). Clinical pharmacokinetics: C. Webber et al., Xenobiotica 33, 625 (2003). Clinical evaluation in irritable bowel syndrome: F. Cremonini et al., Am. J. Gastroenterol. 100, 652 (2005).
Properties: Soly (mg/ml): 33 (pH 3.4), 533 (pH 7.5). pKa 4.48.
pKa: pKa 4.48
 
Therap-Cat: Gastroprokinetic.
Keywords: CCK Antagonist; Gastroprokinetic.

Others monographs:
Methyl Propyl KetoneDevil's ClawChloric AcidN-Methylacetanilide
SmilageninZolamine3',4',5-TrichlorosalicylanilideMethylguanidine
PsicofuranineFlumequineBlack Pepper4',5'-Dibromofluorescein
Sozoiodolic Acidp-AminopropiophenonePhenosafraninp-Ditolylmercury
©2016 DrugLead US FDA&EMEA